Australia's Kazia Therapeutics jumps on positive study for brain tumour drug

Kazia Therapeutics

03/12/2021 03:11

** Oncology-focused drug maker Kazia Therapeutics  KZA.AX 
climbs as much as 6.9% to A$1.48, marking its biggest intra-day
percentage gain since Sept. 23
    ** KZA reports positive final results from a phase II
clinical study of its paxalisib drug for brain tumours
 urn:newsml:reuters.com:*:nASX3j4PFm
    ** Says trial confirmed previously-reported safety and
efficacy results for the drug in treating patients with
glioblastoma — a malignant tumour on the brain or spine that is
almost always fatal
    ** Co says it identified a 60-milligram dose, administered
once daily, as the maximum tolerated dose for the drug
    ** Stock hits highest since Nov. 24
    ** KZA up 19.4% YTD as of last close 
    


 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))